To determine the incidence and epidemiologic characteristics of invasive disease due Haemophilus influenzae, Neisseria meningitidis, group A streptococcus, group B streptococcus, Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus in multiple large diverse U.S. populations
To determine molecular epidemiologic patterns and microbiologic characteristics of public health relevance for isolates causing the above invasive infections
To provide an infrastructure for further research, such as special studies aimed at identifying risk factors for disease, post-licensure evaluation of vaccine efficacy, and monitoring effectiveness of prevention policies
Pathogen-Specific Objectives
Group A streptococcus (GAS)
To determine the distribution of emm types and the association between specific emm types and disease severity in order to guide vaccine development
To track antimicrobial resistance among invasive GAS isolates
To identify potentially modifiable risk factors for community-acquired GAS infections and to identify potentially preventable nosocomial GAS infections such as postpartum and post-surgical infections
Group B streptococcus (GBS)
To assess the impact of CDC prevention guidelines issued in 2002 recommending universal prenatal screening
To determine the extent to which continuing cases of early-onset GBS disease are preventable through current prevention strategies
To monitor the impact of intrapartum prophylaxis on resistance and non-GBS neonatal sepsis
To identify serotypes responsible for disease in order to guide vaccine development
To characterize invasive GBS disease epidemiology and trends in other age groups, particularly late-onset neonatal disease and adult disease.
Haemophilus influenzae
To evaluate progress in the elimination of serotype b disease
To detect possible emergence of disease due to other capsular types.
To evaluate and validate molecular methods to determine or confirm serologic results.
Neisseria meningitidis
To evaluate effectiveness of meningococcal conjugate vaccines and impact on disease burden and herd immunity.
To evaluate the impact of meningococcal conjugate vaccines including changes in molecular epidemiology
To evaluate and validate molecular methods to determine or confirm serologic results.
To evaluate trends in molecular subtypes and the emergence of antimicrobial resistance
Streptococcus pneumoniae
To track emerging antimicrobial resistance in pneumococcal isolates
To evaluate the impact of new pneumococcal conjugate vaccines for infants on disease burden and on antimicrobial resistance
To evaluate prevention among the elderly through pneumococcal polysaccharide vaccine use
To determine the incidence and epidemiologic characteristics of invasive disease due to methicillin-resistant Staphylococcus aureus (MRSA) in diverse geographic areas and to categorize as healthcare-associated or community-associated
To determine the molecular epidemiologic patterns and microbiologic characteristics of healthcare-associated and community-associated MRSA
Date: October 30, 2006
Content source: National Center for Immunization and Respiratory Diseases / Division of Bacterial Diseases
Centers for Disease Control and Prevention,1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435
